Építés alatt – nem éles oldal
Belépés
Taking people in SvédországNo phase

Cardiac Assessment and Takotsubo-stunning Among COPD-exacerbations In-Hospital

Key facts

Where
Gothenburg, SvédországSee the site

Where in Svédország

  • Department of Emergency Medicine and Geriatrics, Sahlgrenska University Hospital/SGothenburg, SvédországTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Sahlgrenska University Hospital
Trial code
NCT06597331
Record updated
2026. szeptember 17.
Original description
The goal of this prospective observational study is to investigate to what extent acute exacerbation of chronic obstructive pulmonary disease (AE-COPD) triggers Takotsubo-stunning, and how this affects the outcome for these patients.Read full original descriptionShow less

Prospective Observational Study of Myocardial Stunning in Patients Hospitalized for Exacerbation of Chronic Obstructive Pulmonary Disease

The goal of this prospective observational study is to investigate to what extent acute exacerbation of chronic obstructive pulmonary disease (AE-COPD) triggers Takotsubo-stunning, and how this affects the outcome for these patients.

The main questions it aims to answer are:

1. What is cumulative incidence of Takotsubo-stunning in patients hospitalized for AE-COPD at Sahlgrenska University Hospital/S (Gothenburg, Sweden)? 2. Among patients hospitalized for AE-COPD at Sahlgrenska University Hospital/S, what is the risk of in-hospital clinical manifestations of acute heart failure in patients with Takotsubo-stunning compared to those without?

Inclusion: Adult patients (≥ 18 years old) admitted to hospital ward for AE-COPD; Inclusion within 72 hours of admission,; Written informed consent.

Exclusion: Expected inability to comply with the protocol (e.g. dementia); Prior acute myocardial infarction or known pre-existing persistent regional wall motion abnormality or left ventricular dysfunction (left ventricular ejection fraction [LVEF] <50%).

ClinicalTrials.gov NCT06597331